Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 2:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Mycobacterium Infection Clear all
Completed Phase 3 Interventional

Nutrition, Immunology and Epidemiology of Tuberculosis

NCT00197704
View directory record Official record
Conditions
Tuberculosis
Interventions
Multivitamins, Placebo
Dietary Supplement · Other
Lead sponsor
Harvard School of Public Health (HSPH)
Other
Eligibility
18 Years and older
Enrollment
876 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2010 · Synced Sep 26, 2026, 2:27 AM EDT
Terminated No phase listed Observational

Utility of MODS for Diagnosis of MDR-TB and Second-Line Antituberculous Drug Susceptibility Testing in Mali

NCT01381757
View directory record Official record
Conditions
Tuberculosis, Pulmonary, Mycobacterium Tuberculous, Antitubercular Agents, Tuberculosis, Mulutidrug-Resistant, Extensively Drug-Resistant, Extensibely Drug-Resistant Tuberculosis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Sep 26, 2026, 2:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

BCG Vaccination Delivered Intradermally, Orally and by Combined Routes

NCT00396370
View directory record Official record
Conditions
Tuberculosis
Interventions
BCG strain Connaught, BCG strain Danish, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 11, 2019 · Synced Sep 26, 2026, 2:27 AM EDT
Completed Phase 2 Interventional

A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.

NCT00000641
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Ciprofloxacin hydrochloride, Ethambutol hydrochloride, Amikacin sulfate, Azithromycin, Rifampin, Clofazimine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
16
States / cities
Torrance, California • Indianapolis, Indiana • St Louis, Missouri + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Sep 26, 2026, 2:27 AM EDT
Completed Phase 4 Interventional Results available

Immediate Versus Deferred Start of Anti-HIV Therapy in HIV-Infected Adults Being Treated for Tuberculosis

NCT00108862
View directory record Official record
Conditions
HIV Infection, Tuberculosis
Interventions
Strategy: Immediate ART, Strategy: Deferred ART
Other
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
13 Years and older
Enrollment
809 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
4
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Sep 26, 2026, 2:27 AM EDT
Completed Phase 3 Interventional

A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or Placebo

NCT00002101
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Ethambutol hydrochloride, Clarithromycin, Rifabutin
Drug
Lead sponsor
Pharmacia
Industry
Eligibility
13 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
44
States / cities
Phoenix, Arizona • Harbor City, California • Irvine, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 26, 2026, 2:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults

NCT04493671
View directory record Official record
Conditions
Pulmonary Disease, Tuberculosis, Pulmonary, Tuberculosis, Multi Drug Resistant Tuberculosis, Drug Sensitive Tuberculosis, Drug-resistant Tuberculosis, Mycobacterium Tuberculosis Infection
Interventions
TBAJ-876 suspension, Placebo suspension, TBAJ-876 100 mg tablet, TBAJ-876 25 mg tablet
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Sep 26, 2026, 2:27 AM EDT
Recruiting Phase 4 Interventional

Hypertonic Saline for MAC

NCT04921943
View directory record Official record
Conditions
Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterium Infection
Interventions
Hypertonic saline, Azithromycin, Ethambutol, Rifampin
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
New York, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Sep 26, 2026, 2:27 AM EDT
Completed Phase 4 Interventional

A Study of Rifabutin, Used Alone or With Ethambutol in the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in Patients With AIDS

NCT00002343
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Ethambutol hydrochloride, Rifabutin
Drug
Lead sponsor
Pharmacia
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 26, 2026, 2:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Effect of TMC207 and Efavirenz in Healthy Volunteers

NCT00992069
View directory record Official record
Conditions
Tuberculosis, HIV
Interventions
Efavirenz (EFV), TMC207
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
5
States / cities
San Francisco, California • Baltimore, Maryland • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 26, 2026, 2:27 AM EDT
Completed Phase 2 Interventional

TBTC Study 25: Study of the Tolerability of Higher Doses of Rifapentine in the Treatment of Tuberculosis

NCT00023426
View directory record Official record
Conditions
Tuberculosis
Interventions
rifapentine
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2005 · Synced Sep 26, 2026, 2:27 AM EDT
Completed Phase 1 Interventional

Diagnostic Effectiveness of Virtual Bronchoscopy

NCT00001515
View directory record Official record
Conditions
Bronchogenic Carcinoma, Chronic Granulomatous Disease, Job's Syndrome, Mycobacterium Infection, Wegener's Granulomatosis
Interventions
virtual bronchoscopy
Device
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 26, 2026, 2:27 AM EDT
Completed No phase listed Observational

Tuberculosis - Learning the Effect of Parasites and Reinforcing Diets

NCT05048485
View directory record Official record
Conditions
Tuberculosis, Pulmonary, Helminthiasis, Malnutrition
Interventions
Not listed
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 26, 2026, 2:27 AM EDT
Completed Phase 2 Interventional

Tolerance, Safety, and Activity of Rifapentine Alone and in Combination Therapy in AIDS Patients With Mycobacterium Avium Complex Bacteremia.

NCT00002192
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Rifapentine, Ethambutol hydrochloride, Clarithromycin, Azithromycin
Drug
Lead sponsor
Anderson Clinical Research
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Hampton, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 26, 2026, 2:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Test the Effects of Itraconazole and Carbamazepine on OPC-167832 in Healthy Men and Women

NCT07542847
View directory record Official record
Conditions
Healthy Volunteers
Interventions
OPC-167832, Itraconazole, Carbamazepine
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 26, 2026, 2:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose Escalation Study of SQ109 in Healthy Adult Volunteers

NCT00866190
View directory record Official record
Conditions
TB Multi-drug Resistant
Interventions
SQ109, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2011 · Synced Sep 26, 2026, 2:27 AM EDT
Terminated No phase listed Observational

Immune Responses to Mycobacterium Tuberculosis (Mtb) in People With Latent Tuberculosis Infection With or Without Concomitant Helminth Infection

NCT02225158
View directory record Official record
Conditions
Latent Tuberculosis Infection
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Bethesda, Maryland • Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 26, 2026, 2:27 AM EDT
Completed Phase 1Phase 2 Interventional

Sildenafil for PNTM Infection

NCT01853540
View directory record Official record
Conditions
Nontuberculous Mycobacterial Infection
Interventions
Sildenafil
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Sep 26, 2026, 2:27 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine

NCT00460759
View directory record Official record
Conditions
Mycobacterium Tuberculosis
Interventions
Moxifloxacin, Rifapentine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Sep 26, 2026, 2:27 AM EDT
Recruiting Phase 2Phase 3 Interventional

Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI

NCT03474029
View directory record Official record
Conditions
Latent Tuberculosis
Interventions
Rifapentine daily for 6 weeks, Rifapentine and Isoniazid weekly for 12 weeks, Rifampin and Isoniazid daily for 12 weeks, Rifampin daily for 16 weeks
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
Not listed
Enrollment
3,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
7
States / cities
Denver, Colorado • Washington D.C., District of Columbia • Manhattan, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 26, 2026, 2:27 AM EDT
Completed Phase 1 Interventional Results available

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis

NCT01585766
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing Forms
Interventions
MEDI-551 30 MG-IV, MEDI-551 60 MG-SC, PLACEBO-IV-SC, MEDI-551 100 MG-IV, MEDI-551 300 MG-SC, MEDI-551 600 MG-IV
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
9
States / cities
Scottsdale, Arizona • Long Beach, California • Sacramento, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2018 · Synced Sep 26, 2026, 2:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers

NCT01674218
View directory record Official record
Conditions
Tuberculosis
Interventions
Moxifloxacin, PA-824, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Sep 26, 2026, 2:27 AM EDT
Completed No phase listed Observational

Tuberculosis Immunity in Children

NCT00170638
View directory record Official record
Conditions
Tuberculosis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 24, 2008 · Synced Sep 26, 2026, 2:27 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of the Practice of Three Morning Sputa on Separate Days for Diagnosis of Mtb

NCT00212550
View directory record Official record
Conditions
Pulmonary TB
Interventions
Obtain standard three daily sputum samples vs. three samples on the first day for the diagnosis of pulmonary TB.
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2016 · Synced Sep 26, 2026, 2:27 AM EDT